Clinical Trial Of DZ13 DNAzyme Targeting C-Jun In Subjects With Basal Cell Carcinoma - DISCovery (Oligonucleotide Inhibition Of Skin Cancer) Study
Funder
National Health and Medical Research Council
Funding Amount
$74,365.00
Summary
Basal cell carcinoma (BCC) is the commonest skin cancer in Australia that is highly invasive. Surgical removal is its main treatment option but causes scarring and is impractical when there are multiple cancers. C-Jun, a molecule promoting cell growth is present in abnormally large amount in BCC compared to normal cells. Dz13 targets and destroys these molecules, killing cancer cells when injected into the tumour. Dz13 may hence become a more effective and aesthetic alternative of treating BCC.